MedPath

The effect of intraoperative remifentanil and sufentanil TCI on postoperative pain and postoperative opioid consumption in breast cancer surgery: A randomized controlled study

Not Applicable
Recruiting
Conditions
Neoplasms
Registration Number
KCT0009226
Lead Sponsor
Chung-Ang University Gwangmyeong Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
86
Inclusion Criteria

Adult female patient with American Society of Anesthesiologists physical status level 1-2 scheduled for breast-conserving surgery under general anesthesia

Exclusion Criteria

- Under 18 years of age or over 70 years of age
- ASA 3 or higher
- BMI 35 or higher
- Pregnant and lactating women
- Patients with serious cardiovascular, liver, kidney, and hematological abnormalities
- Patients with uncontrolled respiratory disease and moderate to severe pulmonary dysfunction
- Those taking opioids, anticonvulsants, or antidepressants
- Those with a history of hypersensitivity or serious side effects to drugs related to this study (opioids, acetaminophen, tramadol)
- During the surgical procedure, the scope of surgery is reduced to a tumor resection or expanded to a total mastectomy.
- Those who refused to participate in this study

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Opioid consumption during 24 hours after surgery
Secondary Outcome Measures
NameTimeMethod
Pain score (11-point NRS) at 30 minutes, 6 hours, 24 hours, and 48 hours after surgery, presence of nausea and vomiting, number of antiemetic drugs administered after surgery
© Copyright 2025. All Rights Reserved by MedPath